Join
Live feed
·
PRReleasevia Quantisnow
RAPT Therapeutics Inc. logo

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

ByQuantisnow·Wall Street's wire, on your screen.
RAPT· RAPT Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RAPT (RAPT Therapeutics Inc.) and more on Quantisnow.